|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/135 | |
| A61K 31/417 | |||
| A61K 31/498 | |||
| A61P 17/06 |
| (11) | Number of the document | 2501373 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10779906.6 |
| Date of filing the European patent application | 2010-11-18 | |
| (97) | Date of publication of the European application | 2012-09-26 |
| (45) | Date of publication and mention of the grant of the patent | 2015-02-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/057184 |
| Date | 2010-11-18 |
| (87) | Number | WO 2011/075267 |
| Date | 2011-06-23 |
| (30) | Number | Date | Country code |
| 621942 | 2009-11-19 | US |
| (72) |
DEJOVIN, Jack, A., US
|
| (73) |
Galderma Laboratories LP,
14501 North Freeway, Fort Worth, TX 76177,
US
|
| (54) | USE OF ALPHA 2 ADRENERGIC RECEPTOR AGONISTS FOR TREATING OR PREVENTING PSORIASIS |
| USE OF ALPHA 2 ADRENERGIC RECEPTOR AGONISTS FOR TREATING OR PREVENTING PSORIASIS |